These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 34209023)

  • 21. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery.
    Du X; Li X; Xiong L; Zhang X; Kleitz F; Qiao SZ
    Biomaterials; 2016 Jun; 91():90-127. PubMed ID: 27017579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
    Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
    Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency.
    Oh JY; Yang G; Choi E; Ryu JH
    Biomater Sci; 2022 Mar; 10(6):1448-1455. PubMed ID: 35229845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.
    Rao S; Richter K; Nguyen TH; Boyd BJ; Porter CJ; Tan A; Prestidge CA
    Mol Pharm; 2015 Dec; 12(12):4424-33. PubMed ID: 26523928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
    Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
    Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesoporous Silica Nanoparticles as a Potential Nanoplatform: Therapeutic Applications and Considerations.
    Djayanti K; Maharjan P; Cho KH; Jeong S; Kim MS; Shin MC; Min KA
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catanionic Hybrid Lipid Nanovesicles for Improved Bioavailability and Efficacy of Chemotherapeutic Drugs.
    Xie X; He D; Wu Y; Wang T; Zhong C; Zhang J
    Methods Mol Biol; 2021; 2211():57-68. PubMed ID: 33336270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal Mesoporous Silica Nanocarriers for Dual Stimuli-Responsive Drug Release and Excellent Photothermal Ablation of Cancer Cells.
    Tran VA; Vo VG; Shim K; Lee SW; An SSA
    Int J Nanomedicine; 2020; 15():7667-7685. PubMed ID: 33116494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
    Zhu Y; Wang B; Chen J; He J; Qiu X
    Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodegradable hybrid mesoporous silica nanoparticles for gene/chemo-synergetic therapy of breast cancer.
    Zhang B; Liu Q; Liu M; Shi P; Zhu L; Zhang L; Li R
    J Biomater Appl; 2019 May; 33(10):1382-1393. PubMed ID: 30880565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances of Using Hybrid Nanocarriers in Remotely Controlled Therapeutic Delivery.
    Li Z; Ye E; David ; Lakshminarayanan R; Loh XJ
    Small; 2016 Sep; 12(35):4782-4806. PubMed ID: 27482950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
    Tang F; Li L; Chen D
    Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment.
    Rosenholm JM; Sahlgren C; Lindén M
    Curr Drug Targets; 2011 Jul; 12(8):1166-86. PubMed ID: 21443474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
    Yasmin R; Tan A; Bremmell KE; Prestidge CA
    J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theragnostic potentials of core/shell mesoporous silica nanostructures.
    Ravindran Girija A; Balasubramanian S
    Nanotheranostics; 2019; 3(1):1-40. PubMed ID: 30662821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles.
    Chen Y; Chen H; Shi J
    Adv Mater; 2013 Jun; 25(23):3144-76. PubMed ID: 23681931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
    Li T; Geng T; Md A; Banerjee P; Wang B
    Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review on the latest developments of mesoporous silica nanoparticles as a promising platform for diagnosis and treatment of cancer.
    Ahmadi F; Sodagar-Taleghani A; Ebrahimnejad P; Pouya Hadipour Moghaddam S; Ebrahimnejad F; Asare-Addo K; Nokhodchi A
    Int J Pharm; 2022 Sep; 625():122099. PubMed ID: 35961417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Mesoporous Silica Nanocarriers in Oncology.
    Baeza A; Vallet-Regi M
    Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current approaches in lipid-based nanocarriers for oral drug delivery.
    Plaza-Oliver M; Santander-Ortega MJ; Lozano MV
    Drug Deliv Transl Res; 2021 Apr; 11(2):471-497. PubMed ID: 33528830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.